Stamping a case of cutaneous adverse drug reaction: Proving beyond causality assessment

Different types of skin testing with a suspected drug have been reported to be helpful in determining the cause of cutaneous adverse drug reactions (CADRs). It is of utmost importance for practicing dermatologists to have a first hand knowledge of different types of skin tests available in a case of...

Full description

Bibliographic Details
Main Authors: Sudip Das, Projna Biswas, Dayamay Pal, Abhishek De
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2018-01-01
Series:Indian Journal of Dermatology
Subjects:
Online Access:http://www.e-ijd.org/article.asp?issn=0019-5154;year=2018;volume=63;issue=2;spage=99;epage=106;aulast=Das
id doaj-f84f4d80cd36451fa4ecff223f7e2304
record_format Article
spelling doaj-f84f4d80cd36451fa4ecff223f7e23042020-11-25T00:20:54ZengWolters Kluwer Medknow PublicationsIndian Journal of Dermatology0019-51541998-36112018-01-016329910610.4103/ijd.IJD_580_17Stamping a case of cutaneous adverse drug reaction: Proving beyond causality assessmentSudip DasProjna BiswasDayamay PalAbhishek DeDifferent types of skin testing with a suspected drug have been reported to be helpful in determining the cause of cutaneous adverse drug reactions (CADRs). It is of utmost importance for practicing dermatologists to have a first hand knowledge of different types of skin tests available in a case of CADR. In each suspected case, a detailed investigation with the suspected agent and correlation of the positive skin reaction with clinical variant of CADR is advocated. Drug skin tests are performed 6 weeks to 6 months after complete healing of the CADR. Drug patch tests are performed similar to the methods used in patch testing in studying contact dermatitis. The commercialized form of the drug used by the patient is tested at 30% dilution. The pure drug is tested at 10% dilution. In severe CADR, drug patch tests should be performed at lower concentrations. It is also of value to test on the most affected site of the initial CADR.http://www.e-ijd.org/article.asp?issn=0019-5154;year=2018;volume=63;issue=2;spage=99;epage=106;aulast=DasCutaneous adverse drug reactionintradermal testpatch testskin prick test
collection DOAJ
language English
format Article
sources DOAJ
author Sudip Das
Projna Biswas
Dayamay Pal
Abhishek De
spellingShingle Sudip Das
Projna Biswas
Dayamay Pal
Abhishek De
Stamping a case of cutaneous adverse drug reaction: Proving beyond causality assessment
Indian Journal of Dermatology
Cutaneous adverse drug reaction
intradermal test
patch test
skin prick test
author_facet Sudip Das
Projna Biswas
Dayamay Pal
Abhishek De
author_sort Sudip Das
title Stamping a case of cutaneous adverse drug reaction: Proving beyond causality assessment
title_short Stamping a case of cutaneous adverse drug reaction: Proving beyond causality assessment
title_full Stamping a case of cutaneous adverse drug reaction: Proving beyond causality assessment
title_fullStr Stamping a case of cutaneous adverse drug reaction: Proving beyond causality assessment
title_full_unstemmed Stamping a case of cutaneous adverse drug reaction: Proving beyond causality assessment
title_sort stamping a case of cutaneous adverse drug reaction: proving beyond causality assessment
publisher Wolters Kluwer Medknow Publications
series Indian Journal of Dermatology
issn 0019-5154
1998-3611
publishDate 2018-01-01
description Different types of skin testing with a suspected drug have been reported to be helpful in determining the cause of cutaneous adverse drug reactions (CADRs). It is of utmost importance for practicing dermatologists to have a first hand knowledge of different types of skin tests available in a case of CADR. In each suspected case, a detailed investigation with the suspected agent and correlation of the positive skin reaction with clinical variant of CADR is advocated. Drug skin tests are performed 6 weeks to 6 months after complete healing of the CADR. Drug patch tests are performed similar to the methods used in patch testing in studying contact dermatitis. The commercialized form of the drug used by the patient is tested at 30% dilution. The pure drug is tested at 10% dilution. In severe CADR, drug patch tests should be performed at lower concentrations. It is also of value to test on the most affected site of the initial CADR.
topic Cutaneous adverse drug reaction
intradermal test
patch test
skin prick test
url http://www.e-ijd.org/article.asp?issn=0019-5154;year=2018;volume=63;issue=2;spage=99;epage=106;aulast=Das
work_keys_str_mv AT sudipdas stampingacaseofcutaneousadversedrugreactionprovingbeyondcausalityassessment
AT projnabiswas stampingacaseofcutaneousadversedrugreactionprovingbeyondcausalityassessment
AT dayamaypal stampingacaseofcutaneousadversedrugreactionprovingbeyondcausalityassessment
AT abhishekde stampingacaseofcutaneousadversedrugreactionprovingbeyondcausalityassessment
_version_ 1725365109012824064